Skip to content
GLP1-US
Prices checked Wegovy pill $149 Wegovy pen $349 Zepbound $299–449 Foundayo from $149 Ozempic $349 Medicare Bridge $50 Compounded sema $175 All prices →

FDA label and CMS Medicare guidance checked Oct 2026

Wegovy for MASH: The Fatty Liver Approval Explained

Wegovy has had accelerated FDA approval since Aug 15, 2025 for MASH, fatty liver with inflammation, when scarring is at stage F2 or F3 and there is no cirrhosis. At 72 weeks, 63% saw the inflammation resolve versus 34% on placebo.

  • Accelerated approval
  • Adults, F2 to F3 only
  • Not for cirrhosis
  • Medicare Part D can cover it

We may earn a commission when you click links to providers, and partner relationships can affect which providers we feature and their order. Advertiser Disclosure

By GLP1-US Editorial TeamUpdated
★ Editor's Choice
Chia Health logo

Chia Health

Our #1 pick for GLP-1 weight loss online

  • One monthly price: clinician, medication and free shipping included
  • Semaglutide or tirzepatide, as a weekly injection or a daily tablet
  • No insurance needed; HSA/FSA and Klarna accepted

Compounded medications, not FDA-approved. Prices checked Nov 17, 2026. Advertiser Disclosure

$212.89 first month, then $349/mo

6-month plan: $249/mo, paid upfront ($1,396.89 for the first 6 months). Microdose: $109.19 first month, then $179/mo.

Get Started Read our Chia Health review

01 The approval

What the FDA Approved for Wegovy MASH

MASH, metabolic dysfunction-associated steatohepatitis, is the new name for NASH: fat in the liver plus inflammation and cell damage, which can scar the liver over years. The Wegovy label covers "noncirrhotic MASH ... with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults," with a reduced-calorie diet and more activity.

Approved
Aug 15, 2025

accelerated approval

Who
Adults, F2 to F3

no cirrhosis

Dose
2.4 mg/week

1.7 mg if not tolerated

Form
Injection only

not the pill, not HD

Accelerated approval The FDA approved this use on biopsy results (less inflammation and scarring), not yet on fewer cases of cirrhosis, liver failure or transplant. The label says "continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial." ESSENCE runs to 240 weeks to answer that.

02 Trial results

ESSENCE Results at Week 72

ESSENCE randomized 800 adults 2:1 to Wegovy or placebo on top of standard care. Each had a liver biopsy at the start and at week 72, read by two pathologists. Median age was 57 and median BMI 34; 41% had a BMI of 35 or more, and 7% had a BMI under 25.

Week 72 biopsyPlacebo (n=266)Wegovy (n=534)
Steatohepatitis resolved, fibrosis not worse
+29 points (21 to 36)
34% 63%
Fibrosis improved 1+ stage, steatohepatitis not worse
+14 points (8 to 21)
22% 37%
Both: steatohepatitis resolved and fibrosis improved
+17 points (10 to 23)
16% 33%

Source: Wegovy prescribing information, section 14.4, Table 21. Novo Nordisk reports the unrounded rates as 62.9% vs 34.3% and 36.8% vs 22.4%.

Liver enzymes ALT and AST fell more on Wegovy from week 12 onward. A separate post hoc analysis of the STEP UP weight-loss trial, shown at EASD 2026, looked at liver fat (liver-fat data); it is not part of the MASH approval.

03 Eligibility

Who Qualifies for Wegovy for MASH

  • 1

    Adult with a MASH diagnosis. The trial required a biopsy. In practice, doctors also stage fibrosis with blood scores such as FIB-4 and liver stiffness scans such as FibroScan; ask which evidence your plan accepts.

  • 2

    Fibrosis stage F2 or F3. F0 to F1 (little or no scarring) and F4 (cirrhosis) are outside the label.

  • 3

    No BMI cutoff on the label. Unlike the weight indication, the MASH use does not name a BMI; most trial patients had obesity, and 3% had "lean MASH."

  • 4

    Diabetes is allowed. 56% of ESSENCE patients had type 2 diabetes. Wegovy is not combined with Ozempic or another GLP-1.

  • 5

    No medullary thyroid cancer or MEN 2 in you or your family, per the label contraindications.

Ro's insurance concierge checks Wegovy coverage and files the prior authorization. Ro Body membership $74 to $149 a month, medication billed separately (Oct 2026).

Have Ro check your Wegovy coverage

04 Insurance

Wegovy MASH Insurance and Medicare

MASH is a liver diagnosis, so a weight-loss exclusion does not automatically apply. UnitedHealthcare, for example, covers Wegovy injection for MASH with prior authorization under the same policy as heart risk, on plans that exclude weight loss (UnitedHealthcare). Other plans: Aetna, Cigna, Blue Cross.

Medicare Part D

CMS lists noncirrhotic MASH with moderate to advanced fibrosis as a Part D use. Your plan's formulary copay and prior authorization apply.

Not the $50 Bridge

CMS says people with this diagnosis are ineligible for the GLP-1 Bridge, even if their Part D plan does not cover the drug. See Medicare GLP-1 Bridge.

Commercially insured and approved? The Wegovy savings card can bring a fill to as little as $25 (maximum savings $100 a month). Without coverage, NovoCare self-pay is $349/mo for the pen; the MASH dose costs the same as lower doses. More: Wegovy cost.

05 Safety

Side Effects and Liver Safety

Side effects are the usual semaglutide ones, mostly nausea, diarrhea, constipation and vomiting during the dose climb. Label warnings include pancreatitis, gallbladder disease, acute kidney injury from dehydration and the thyroid C-cell boxed warning. Gallbladder problems matter more with liver disease, so report pain in the upper right abdomen. Full list: Wegovy side effects.

06 FAQ

Wegovy MASH FAQ

Is Wegovy FDA-approved for fatty liver disease?
For one form of it. On August 15, 2025, the FDA granted Wegovy accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis (stages F2 to F3) in adults, with diet and exercise. Simple fatty liver without inflammation, early fibrosis (F0 to F1) and cirrhosis (F4) are not on the label.
What does accelerated approval mean for Wegovy MASH?
The FDA approved it on liver biopsy improvements at 72 weeks, which are expected to predict fewer cirrhosis and liver events but have not shown that yet. The label says continued approval may depend on a confirmatory trial. The same ESSENCE trial continues to 240 weeks to measure those outcomes.
How well does Wegovy work for MASH?
In the ESSENCE trial of 800 adults with F2 or F3 fibrosis, steatohepatitis resolved without worse fibrosis in 63% on Wegovy versus 34% on placebo at week 72. Fibrosis improved by at least one stage without worse steatohepatitis in 37% versus 22%. Weight fell 10.5% versus 2%.
Does Medicare cover Wegovy for MASH?
Through Part D only. CMS lists noncirrhotic MASH with moderate to advanced fibrosis as a Part D use, and people with that diagnosis cannot get Wegovy through the $50 GLP-1 Bridge, even if their Part D plan does not cover it. Ask your plan about its prior authorization criteria.
Is the Wegovy pill approved for MASH?
No. The MASH indication is on Wegovy injection only. The tablet is approved for weight management and heart-risk reduction in adults. The MASH dose is the 2.4 mg weekly injection, or 1.7 mg if 2.4 mg is not tolerated.
Are there other FDA-approved drugs for MASH?
Yes. Rezdiffra (resmetirom), approved in March 2024, was the first drug for noncirrhotic MASH with F2 to F3 fibrosis, also under accelerated approval. Wegovy was the second and is the only GLP-1 with the indication. Your hepatologist chooses based on your weight, diabetes and other medicines.

Other approved uses: what GLP-1 is used for · Wegovy for heart risk · Zepbound for sleep apnea.

Medical Disclaimer

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or qualified health provider with any questions about a medical condition or medication. Never disregard professional medical advice or delay seeking it because of something you have read on this website.

Checked against primary sources such as FDA labels, CMS and provider pages
Updated
How we check facts →